Wednesday 16 June

Patents in pandemics: A force for good

When and where

Date and time

Start: Wednesday 16 June 2021, 06:00 PM

End: Wednesday 16 June 2021, 07:00 PM

Event Overview

President Joe Biden has said that the United States would support a proposal to waive intellectual property rights to COVID-19 vaccines during the pandemic. Many around the world saw his announcement as a victory for greater equity in vaccine distribution, in which lower income countries are lagging far behind wealthier ones.

But scientists, supply chain experts and a number of world leaders have argued that patents are not the problem and say that the real bottleneck lies in the complexity of the manufacturing process, a lack of local production capacity and the scarcity of the highly specialised raw materials.

Where does the truth lie? What are the real priorities and challenges to ramping up vaccine manufacture and distribution in low and middle income countries?

Join our experts for a discussion of these issues on 16 June at 6pm




Dr Anne Moore, Centre for Global Development, University College Cork, Ireland

Dr Anne Moore, Centre for Global Development, University College Cork, Ireland

Dr. Anne Moore graduated with a degree in Biochemistry University College Cork. She completed a PhD in HIV vaccine immunology with Professor Kingston Mills. Dr. Moore subsequently embarked upon post-doctoral work on defects in immune responses in HIV-infected individuals in the Wistar Institute in Philadelphia and further work on recombinant vaccines against viruses such as HIV and Ebola virus in Dr. Gary Nabel’s lab then at the University of Michigan. As a senior immunologist in Prof. Adrian Hill’s group in the University of Oxford, she developed several T cell inducing vaccine candidates against malaria and TB and was involved in clinical trials of these and other vaccine candidates in Oxford and malaria endemic areas in Africa. In 2016 she worked for 10 months with the vaccine biotech company, Vaxart, South San Francisco while on sabbatical. Here she worked on tablet-based oral vaccines for a range of therapeutic and prophylactic vaccine.

Simon Wright, Schlich Ltd

Simon Wright, Schlich Ltd

Simon has a Chemistry (with Biochemistry) degree from Bristol University and qualified as a UK patent attorney in 1990. He became a European Patent Attorney in 1992 while working with Kilburn & Strode and joined J A Kemp in 1994. He became a partner in J A Kemp’s biotechnology group in 2005 and moved to Schlich on the south coast in January 2022.

Simon handles patent (and trade mark) work in a wide variety of life science and pharma fields, including stem cells, human genes and genomics, drug delivery systems, contrast agents, GM crops and CRISPR technology. He works for a broad variety of clients ranging from individual/private clients, UK universities and biotechnology start-ups, US genomics and academic institutions all the way up to European and US-based multinational corporations.

Simon is the Chairman of CIPA’s Life Sciences Committee and is a member of CIPA’s Council, Patents Committee and International Liaison Committee. He is Secretary of the epi’s Biotechnological Inventions Committee and a member of epi Council and the By-Laws committee. He enjoys drinking wine, playing the sax, running and cycling.

Gwilym Roberts, Honorary Secretary, CIPA

Gwilym Roberts, Honorary Secretary, CIPA

Gwilym Roberts advises clients on all aspects of the patent process including IP audit and capture, IP filing strategies and patent portfolio management techniques. He acts for a range of clients including individuals, SMEs, Universities, and spin outs through to multi-nationals and handles a broad and diverse range of cases before the UK Patent Office, EPO and WIPO.

Prof Robin Shattock, Head of Mucosal Infection and Immunity, Imperial College, London

Prof Robin Shattock, Head of Mucosal Infection and Immunity, Imperial College, London

Professor Robin Shattock is the Head of Mucosal Infection and Immunity within the Department of Medicine at Imperial College London. Professor Shattock’s research focuses on the mechanisms of mucosal infection and the development of novel preventative strategies appropriate to a developing world setting. This has led to the establishment of international collaborations aimed at preclinical identification, development and selection of HIV microbicide and vaccine candidates prior to formal clinical efficacy trials.

Professor Shattock oversees a portfolio of research that is supported by 26 members of staff including researchers, PhD students, clinical trial managers and project managers. Professor Shattock has published over 160 peer-reviewed articles in this area and secured funding from the European Commission, Bill and Melinda Gates Foundation, Wellcome Trust, MRC and the NIH.

The event has been added to your basket:

Patents in pandemics: A force for good

Proceed to basket

Shopping Basket

No products in the cart.

Are you a CIPA member?

Sign in to your account to register for the event

Forgotten password?

If you are not yet registered or a member of CIPA, please register here

Skip to content